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Background: Gender disparity in melanoma outcome is consistently observed, suggesting that gender is as an
important prognostic factor. However, the source of this gender disparity in melanoma remains unclear.
Objective: This article reviews advances in our understanding of gender differences in melanoma and how such
differences may contribute to outcomes.
Methods: A broad literature search was conducted using the PubMed database, with search terms such as ‘gender dif-
ferences in melanoma’ and ‘sex differences in melanoma.’ Additional articles were identiﬁed from cited references.
Results:Herein, we address the gender-linked physiologic differences in skin andmelanoma.We discuss the inﬂuence
of estrogen on a woman’s risk for melanoma andmelanoma outcomes with regard to pregnancy, oral contraceptives,
hormone replacement therapy, and UV tanning.
Conclusions:Thepublishedﬁndingsongenderdisparities inmelanomahaveyieldedmanyadvances inourunderstand-
ing of this disease. Biological, environmental, andbehavioral factorsmayexplain theobserved gender difference inmel-
anoma incidence and outcome. Further research will enable us to learnmore aboutmelanoma pathogenesis, with the
goal of offering better treatments and preventative advice to our patients.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The incidenceof cutaneousmelanoma(CM)continues to increase in the
Caucasian population in the United States. In 2014, women only accounted
for42%of the76,100newmelanomacases andonly33%of the9,710deaths
associated with CM in the United States [1]. These trends are consistently
observed in populations around theworld. Indeed, gender disparity inmel-
anomaoutcome is so consistently observed that gender has been suggested
as an important prognostic factor, despite not being formerly incorporated
in staging algorithms [2]. The source of this gender disparity in melanoma
remains unclear, but likely represents both biological and behavioral
etiologies. Here, we review the current knowledge of how the disease
of melanoma differs between men and women.
Gender-linked physiologic differences in skin
Skin is a dynamic, complex, integrated arrangement of cells, tissues,
and matrix elements that mediates a diverse array of functions, includ-interest.
le. For citation purposes, please
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Inc. on behalf of Women's Dermating physical permeability barrier, protection from infectious agents,
thermoregulation, sensation, ultraviolet (UV) protection, wound repair
and regeneration, and outward physical appearance. These various
functions of skin are mediated by its major layers: the epidermis, der-
mis, and subcutaneous fat. The dermis contains water, ground sub-
stance, and elastic ﬁbers that, in combination with the layer of
subcutaneous fat, account for the majority of the skin’s thickness. The
thickness of the skin is greater in men than in women at all ages [3,4].
Skin thickness decreases in men and women starting at the age of 45,
and women’s skin gets 10% thinner after menopause [5,6]. Skin color is
modulated by melanin, hemoglobin, and other chromophores. Melanin
is synthesized in melanocytes, dendritic cells located in the basal layer
of the epidermis. Melanocytes are known to be differently distributed
according to anatomic sites. No gender-related difference has been
reported; however, within individual ethnic groups, men have been
reported to have darker skin color [7], which may be related to a more
vascularized upper dermis [8] and more melanin synthesis [9]. These dif-
ferences are likelymodulated, in part, by hormones, given that theyman-
ifest during puberty and increase with age [10].
Men and women differ in the metabolism of and response to andro-
gens and estrogens [11]. Estrogens are known to accelerate wound
healing, improve inﬂammatory disorders, increase epidermal thickness,
and protect against photoaging of the skin [12]. The cellular effects of es-
trogens are mediated by estrogen receptors (ERs), ERα and ERβ, whichologic Society. This is an open access article under the CC BY-NC-ND license (http://
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ERβ are widely expressed in human tissue, but have differential distri-
butions in various tissues, including the skin. ERα is primarily expressed
in the uterus, liver, kidneys, breasts, and heart, whereas ERβ is primarily
detected in what are known as nonclassical estrogen-responsive tissues:
the ovaries, colon, lungs, adipose tissue, prostate, bladder, and skin [13].
Notably,melanomas do express ERβ, but its expression does not differ be-
tween male and female tumors [14]. Cutaneous ER levels are generally
known to be higher in women as compared with men. However, relative
levels of ERα and ERβ in men and women are not well understood. In
women, the amount of ERs declines after menopause with declining
levels of estradiol, which, through positive feedback, has a pro-synthetic
effect on ERs [13]. Expression declines more rapidly in ERβ than in ERα,
resulting in an increasedERα:ERβ ratio in the skin. In contrast to estrogens,
androgens—such as testosterone and 5α-dihydroxytestosterone—may
be able to promote melanoma tumorigenesis. Androgen receptors, which
have a similar mechanism of action as estrogen receptors, have been de-
scribed in human melanoma cells [15,16].
There are also several baseline differences in the immune systems of
men and women. On average, women have higher measured IgG and
IgM levels, as well as a greater percentage of CD3+ T lymphocytes, as
compared with men, suggesting that men have a relative attenuation of
the adaptive immune response comparedwithwomen [17]. This is further
evidenced by observations that men are more susceptible to bacterial and
viral infections [18], while women are more prone to autoimmune and
inﬂammatory diseases [19]. Men are also more prone to skin cancer; this
increased risk may be partly explained by their heightened susceptibility
to ultraviolet-induced immunosuppression compared with women [20].
Ultraviolet (UV) irradiation is known to inhibit contact hypersensitivity or
delayed-type hypersensitivity. Also, the sex hormones may have an
additional differential effect on immune cells, as both estrogen and andro-
gen receptors are expressed in immune cells [21].
The mechanisms and mechanics of oxidative stress also differ be-
tween sexes. By-products of oxygen metabolism lead to the production
of reactive oxygen species (ROS), which can damage a wide range of
molecules, leading to oxidative stress [22]. Male cells of various tissue
types have an elevated ROS cellular environment, due to the expression
of lower levels of antioxidant enzymes as compared with females [23].
Additionally, estrogens appear to have direct antioxidant and protective
effects, while testosterone may potentiate oxidative stress. This differ-
ence between testosterone and estrogen may contribute to disparities
in melanoma outcome [24].
Gender-speciﬁc differences in melanoma
Gender-speciﬁc differences in melanoma epidemiology are well
established. The probability of developing melanoma during one’s lifetime
is 1.72% in males and 1.22% in females [25]. In the Netherlands, a large
population-based cohort study including 10,538 melanoma patients from
1993 to 2004 analyzed the gender difference in melanoma survival after
adjusting for tumor-related variables (Breslow thickness, histology, tumor
site, and metastatic and nodal status). They found that the relative excess
risk of mortality was 2.70 (95% CI [2.38, 3.06]) in males versus females. The
female survival advantage remained after adjusting formultiple confounding
variables, including tumor thickness [26]. Gamba et al. [27] analyzed data
from 26,107 individuals, aged 15–39 years, from the U.S. National Cancer In-
stitute’s Surveillance, Epidemiology, and End Results registry. They reported
that youngmen had a 55% lower rate of melanoma survival compared with
age-matched youngwomen, and concluded thatmale sex, within all speciﬁc
age groups and across all tumor thickness categories, histologic subtypes, and
anatomic sites, is associated with a disproportionate burden of melanoma
deaths.Apopulation-basedcohort study including11,774melanomapatients
from theMunich Cancer Registry (Germany) analyzed gender differences in
survival anddiseaseprogressionacross all stagesof CM. Localizedmelanomas
in women showed a lower risk of metastasis, resulting in better survival
when compared with men, even after ﬁrst disease progression [28]. Inlocalized melanoma, men generally had worse characteristics at diagnosis,
such as older age; increased likelihood of having an ulcerated or thicker pri-
mary tumor; and melanomas more commonly located on the head, neck,
and trunk instead of the extremities. However, even after diagnosis,
men continue to have disadvantages compared with women [28]. In
various studies, women showed a longer delay before relapse and a
higher cure rate compared to men [26,28]. Table 1 summarizes the
sex risk estimates of melanoma survival in various studies.
The natural history ofmelanoma inwomen parallels the physiologic hor-
monal changes theyexperience. The incidenceofmelanoma is rarebeforepu-
berty, rises abruptly through the reproductive ages until approximately 50
years of age, and then diminishes after menopause [33]. In agreement with
the aforementioned survival advantages of young women and womenwith
localized melanoma, women who present with stage IV disease also show
higher survival rates compared to men, who have a two-fold greater death
rate from melanoma [34]. Kemeny et al. [35] also reported that premeno-
pausal women show a higher survival rate compared to postmenopausal
women, which was more pronounced in women with advanced disease.
Although the survival advantage decreases with age, postmenopausal
women still have better rates of survival compared with men.
Gender disparity in melanoma may have genetic underpinnings.
Kocarnik et al. [36] conﬁrmed eight single nucleotide polymorphisms that
modulate melanoma risk. Interestingly, one single nucleotide polymor-
phism, rs16891982, in the SLC45A2 gene inﬂuenced melanoma risk differ-
ently by sex, with higher risk association observed in males (OR 5.5 in
males vs. 2.37 in females). The SLC45A2 gene codes for an ion transporter
protein in themelanosomeand likely shapesmelanoma risk bymodulating
melanosomeactivity by changing the internal pH [37].Notably, estrogen in-
creases expression of tyrosinase [38], the rate-limiting enzyme in melanin
production located in themelanosome, and rs16891982 has been associat-
ed in this enzyme’s activity and expression [39]. Synthesizing these obser-
vations, Kocarnik et al. [36] hypothesize that the gender-modiﬁed risk
associated with rs16891982 may be mediated through hormonal inﬂu-
ence on a critical enzyme in melanogenesis. While this study explored
inherited germline polymorphisms, inherent differences in genetic bur-
den or immunogenicity of the tumors themselves are an intriguing, yet
poorly explored, area of research.
Estrogen and melanoma
The most widely studied mechanism regarding gender disparity in
melanoma is the inﬂuence of sex hormone levels and estrogen receptor
expression. Various laboratory studies with cultured cells and animal
models support a role for estrogens in contributing to the better survival
rates amongwomen. Kanda andWatanabe [40] showed that incubation
of 17-β-estradiol inhibited the growth of human metastatic melanoma
cells in vitro, and concomitantly reduced constitutive interleukin-8
(IL-8) mRNA and secretion. The melanoma cell growth inhibited by
17-β-estradiolwas counteracted by exogenously added IL-8, which sug-
gests that estrogen mediates growth suppression in melanoma cells by
inhibiting IL-8 expression. Of note, this effect was only observed in ER-
positive cells, indicating that estrogen may mediate an inhibitory effect
on melanomas via ER and IL-8 in vitro. Richardson et al. [41] and Roy
et al. [42] reported that 17-β-estradiol inhibited the invasive activity
of melanoma cells, but did not have antitumor activity in C57BL/6
mice inoculated with syngeneic B16 tumors. Cho et al. [43] reported
that implanted B16 murine melanoma cells grew more rapidly in ERβ
knockout mice compared to congenic C56BL/6 mice with intact ERβ,
therefore suggesting that the presence of ERβ was protective against
tumor growth. It has been demonstrated that melanocytic lesions
express detectable levels of ERα and ERβ mRNA and protein [44,45].
However, ERβ was the predominant ER type in melanocytic lesions,
indicating that estrogen might play a role in melanocyte physiology
via ERβ [44]. ERβ immunoreactivity of melanoma cells was dependent
on the microenvironment: melanoma cells in close contact with
keratinocytes were more reactive than invasive melanoma, and the
Table 1
Summary of Selected Studies Demonstrating Female Survival Advantage.
Reference Year End Point Country No. of Patients Adjusted Risk Estimates1 95% CI
Balch et al. [29] 2001 DSS United States 13,581 0.84 0.76 to 0.92
de Vries et al. [26] 2008 RS The Netherlands 10,538 0.532,3 0.48 to 0.61
Xing et al. [30] 2010 DSS United States (SEER) 37,519 0.673 0.60 to 0.75
Joosse et al. [28] 2011 DSS Germany 11,774 0.62 0.56 to 0.70
Collins et al. [31] 2011 DSS4 United States (SEER) 142,653 0.653 0.62 to 0.68
Thompson et al. [32] 2011 DSS International AJCC Consortium 10,233 0.69 0.61 to 0.79
Abbreviations: AJCC, American Joint Committee on Cancer; DSS, disease-speciﬁc survival; RS, relative survival (estimate of DSS).
1 Relative risk of women compared with men; presented as hazard ratio unless otherwise speciﬁed.
2 Presented as relative excess risk.
3 Value reported here is the inverse of the original risk estimate, because men were compared with women in the cited publication.
4 For patients who underwent surgery.
S13M.R. Roh et al. / International Journal of Women's Dermatology 3 (2017) S11–S15ERβ protein expression decreased progressively with increased Breslow
thickness and resulted in more invasive melanoma [46]. Another study
demonstrated that ERβ expression in CMs without and with lymph
node metastases were higher and lower, respectively, than in the
healthy skin surrounding them, suggesting a role for ERβ in the meta-
static process of melanoma [44]. Together, these studies suggest that
the loss of ERβ expression may be an important step in melanoma
progression and/or the stimulation of melanoma proliferation.
Pregnancy, oral contraceptives, and hormone replacement therapy
Approximately one third of all women diagnosed with CM are of
childbearing age [47]. The observation of physiological hyperpigmenta-
tion on multiple cutaneous sites during pregnancy yielded the hypothe-
sis that pregnancy-related hormonesmight inﬂuence the course of CM in
women. Pregnancy is also considered to be a state of immunosuppres-
sion, one that helps prevent the rejection of the fetus expressing paternal
alloantigens [48]. However, recent studies found no signiﬁcant
dermatoscopic or abnormal histologic changes in nevi during pregnancy
[49]. Also, clinical, epidemiologic, and laboratory studies have found that
pregnancy does not signiﬁcantly change the characteristics or prognosis
of CM [50]. Multiple controlled studies in the 1980s consistently showed
no signiﬁcant impact on the survival of women diagnosedwith localized
melanoma (AJCC stage I or II) during pregnancy [51–56]. Since pregnan-
cy does not seem to inﬂuence the prognosis or evolution of localizedma-
lignant melanoma, the recommendations set forth by the European
Society ofMedical Oncology for evaluating a patient diagnosedwithmel-
anoma remain the same regardless of pregnancy status [57]. Counseling
patients diagnosed with melanoma regarding future pregnancies and
hormone replacement therapy should be based on established prognos-
tic factors. If poor prognostic factors exist, clinicians will often advise pa-
tients to wait 2 to 3 years to become pregnant, thereby avoiding
pregnancy during the window of time with the highest likelihood of re-
currence [50]. However, there are no standardized guidelines for the
postponement of the further pregnancies after the diagnosis of melano-
ma; counseling must be individualized for each patient, taking into con-
sideration her age, fertility status, availability of oocyte cryopreservation,
disease prognosis, and family support.
Multiple studies have investigated the relationship between the use of
oral contraceptives (OCs) and the risk of CM, including two recently pub-
lished meta-analyses. The ﬁrst of these, an analysis of 18 studies, reported
an overall OR of 0.95 (95% CI [0.82, 1.15]) [58]. The second, an analysis of
10 studies encompassing 3,796 cases and 9,442 controls, also reported a
summation OR of 0.95 (95% CI [0.87, 1.04]) [59]. The authors of a pooled
analysis of 10 case–control studies also failed toﬁndan associationbetween
risk of CM and ever-use of OCs (pooled OR, 0.86; 95% CI [0.74, 1.01]) [60].
There were also no relationships between risk of melanoma and OC length
of use, age at ﬁrst use, or current use. These studies all make the consensus
conclusion that there is no evidence of a relationship between risk ofmela-
noma and use of OCs. Based on a limited number of studies, a similar con-
clusion has been made regarding the relationship, or lack thereof,
between hormone replacement therapy (HRT) and risk of malignantmelanoma. Gupta and Driscoll [61] analyzed 12 studies, 10 of which
showednoassociationbetweenuse ofHRT andmelanoma. The two studies
that showed increased risk of melanoma with HRT use did not control for
potential confounding variables. Consequently, a history of localized mela-
noma is not considered a contraindication for the use of HRT.
UVA tanning: a major melanoma risk factor for young women
Melanoma is the most prevalent cancer among 25- to 29-year-old
females, and under the age of 40, women have a higher incidence of
melanoma than men [62]. In several studies, risky tanning behavior
was more common among women, younger people, and people of
low socioeconomic status [63]. These emerging data on the incidence
rates of skin cancers in young women younger than age 40 years com-
pared with men of that age group suggest that the etiology is partly
due to excessive, repeated exposures to unnaturally large amounts of
ultraviolet A (UVA) light from UVA-rich lamps. Indoor tanning has
been widely practiced in northern Europe and the United States since
the 1980s [64]. Indoor tanning equipment mainly emits light in the
UVA range, but a fraction (b5%) of this spectrum is in the ultraviolet B
range [65]. In frequent users of UVA-rich lamps, the amount of annual
UVA exposure is roughly doubled. It was also reported that high-
pressure UVA tanning beds, with dose rates up to 13 times that of the
summer sun, have the potential to quadruple the annual UVA exposure
of frequent tanners [66]. Two recent meta-analyses [65,67] reported
that the risk of CM is increased by 16% and 20%, respectively, for those
who have ever used indoor tanning devices. Even more concerning,
the risk of melanoma doubled when use started before the age of 35
years. These ﬁndings—that early exposure and more frequent use of
indoor tanning beds signiﬁcantly increases the risk of melanoma—
represent a global trend [65]. Therefore, in 2009, the International
Agency for Research on Cancer classiﬁed the entire ultraviolet spectrum
and indoor tanning devices as carcinogenic to humans (group 1) [68].
This classiﬁcation was based on evidence from basic and epidemiologic
studies demonstrating that UVAhas an important role in skin carcinogen-
esis [69] and that UVA-producing tanning lamps are capable of inducing
the types of DNA damage associated with photocarcinogenesis [70].
As melanomas arising in young women are commonly associated
with tanning bed use, these diseases can beminimized by educating pa-
tients to avoid artiﬁcial tanning habits and strongly regulating their use.
The World Health Organization, the International Commission on Non-
Ionizing Radiation Protection, and the European Society of Skin Cancer
Prevention have all maintained that the highest regulatory priorities
should be the restriction of sunbed use by people younger than 18
years of age and the banning of unsupervised indoor tanning facilities.
Such restrictions have been implemented in Australia and several
European countries, including Austria, France, Germany, Portugal,
Belgium, Scotland, and Spain.
In May 2014, the U.S. Food and Drug Administration formally
reclassiﬁed sunlamp products and UV lamps intended for use in sun-
lamp products from low-risk (class I) tomoderate-risk (class II) devices.
Along with this reclassiﬁcation came the mandate that all sunlamp
S14 M.R. Roh et al. / International Journal of Women's Dermatology 3 (2017) S11–S15products carry a visible black-box warning on the device that explicitly
states that the sunlamp product should not be used on persons younger
than 18 years of age. Furthermore, certain marketing information associ-
ated with these devices must provide additional and speciﬁc warning
statements and contraindications (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm399222.htm).On legislative fronts,
only nine states (CA, DE, IL, LA, MN, NV, OR, TX, and VT) have banned
access to indoor tanning for adolescents younger than age 18 years.
Conclusion
Mounting evidence suggests that both biological and environmental
factors explain observed gender differences inmelanoma incidence and
outcome. Innate gender differences in hormones, immune homeostasis,
and oxidative stress likely contribute to the sexual disparity in melano-
ma survival. Beyond these innately biological differences, behaviors,
such as tanning bed use, also clearly shapemelanoma risk. Understand-
ing gender differences allows for targeted interventions. For instance,
increased awareness of the modiﬁable risks of tanning behavior has
yielded bans in nine states, with pending legislation in additional states
that promises to explicitly ban under-18 indoor tanning. Similarly, bet-
ter understanding of innate biological differences inmelanomabetween
the genders may yield improved targeted therapies.
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